Long non‑coding RNA NNT‑AS1 contributes to cell proliferation, metastasis and apoptosis in human ovarian cancer

Abstract

Ovarian cancer is a markedly heterogeneous malignancy characterized by various histological subtypes. Molecular biomarkers have been indicated to serve significant functions in the early diagnosis and treatment of early-stage ovarian cancer. However, the detailed mechanism underlying the tumorigenesis of ovarian cancer remains unclear. The present study aimed to identify a novel long non-coding RNA in patients with ovarian cancer. Nicotinamide nucleotide transhydrogenase-antisense 1 (NNT-AS1) was markedly downregulated in patients with ovarian cancer and in cultured human ovarian cancer cells. Knockdown of NNT-AS1 in the human ovarian cancer cell lines HO-8910 and SK-OV-3 promoted colony formation and arrested the cell cycle at G/G phase. Furthermore, Transwell demonstrated that the downregulation of NNT-AS1 increased cell migration and invasion by ~60 and 70%, respectively, in HO-8910 and SK-OV-3 cells. Furthermore, cell apoptosis was inhibited by the transfection of siNNT-AS1 in the two cell lines, whereas the relative activities of caspase-3 and caspase-9 were decreased. These results indicated a protective function of NNT-AS1 in human ovarian cancer, providing novel insights into the diagnosis and treatment of ovarian cancer in clinical settings.

The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease

“…It is worth noting that NNT-AS1 was down-regulated in studies [34,[37][38][39] on ovarian cancer, triple-negative breast cancer, and gastric cancer, which is inconsistent with the results of the others [32,33,35,36]. These differences need to be further verified in large-scale experiments, and the connection between NNT-AS1 and sex hormones and sex hormone receptors deserves more in-depth exploration.…”

“…A recent bioinformatics study based on Gene Expression Omnibus (GEO) data analyzed the expression of lncRNA in triple-negative breast cancer (including ER-negative), in which NNT-AS1 was also found to be down-regulated [38]. In addition, in a study on ovarian cancer, the low level of NNT-AS1 was confirmed as well [39].…”

Long non‑coding RNA NNT‑AS1 knockdown represses the progression of gastric cancer via modulating the miR‑142‑5p/SOX4/Wnt/β‑catenin signaling pathway

“…The lncrna nicotinamide nucleotide transhydrogenase-antisense rna1 (nnT-aS1), located at 5p12 with 3 exons, is a newly identified lncRNA (7). NNT-AS1 has been reported to be involved in the progression of lung, ovarian, breast and gastric cancer, as well as osteosarcoma (8)(9)(10)(11)(12)(13). it has also been reported that nnT-aS1 expression was increased in Gc tissues and cell lines (14); however, the molecular mechanism underlying nnT-aS1 in Gc is not completely understood and requires further investigation.…”

Upregulated Expression of LncRNA Nicotinamide Nucleotide Transhydrogenase Antisense RNA 1 is Correlated with Unfavorable Clinical Outcomes in Cancers

“…Compared with adjacent noncancerous tissue and normal cell, upregulated NNT-AS1 expression was identi ed in most cancer tissues or cell lines and therefore indicated poor survival outcome, such as osteosarcoma [27], breast cancer [19], cervical cancer [26], gastric cancer [28], hepatocellular carcinoma [18], colorectal cancer [21], and non-small cell lung cancer (NSCLC) [2]. On the contrary, another study performed by Huang et al, claimed that NNT-AS1 was markedly downregulated in patients with ovarian cancer and ovarian cell lines [29]. However, results from above-mentioned studies should be interpreted with caution because of the limited sample size and discrete outcomes.…”